Diadem

Diadem to Discuss Biomarker Blood Tests for Alzheimer's Disease at TD Cowen Liquid Biopsy Summit

Retrieved on: 
Monday, December 4, 2023
Alzheimer's disease, Dementia, Patient, Spondyloarthropathy, Mandarin Oriental Hotel Group, Microsoft Support Diagnostic Tool, Diadem, Medical imaging, Pharmaceutical industry, Research

MILAN and NEW YORK , Dec. 4, 2023 /PRNewswire/ -- Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer's disease (AD), today announced that Chief Executive Officer Paul Kinnon will participate in the TD Cowen Liquid Biopsy Summit, to be held at the Mandarin Oriental Hotel in New York City on December 5, 2023. Mr. Kinnon will serve as a panelist on the Beyond Cancer Panel scheduled from 2:40-3:40 pm ET that day, which will be hosted by Daniel Brennan, Cowen Managing Director, Research, Health Care - Life Science & Diagnostic Tools.

Key Points: 
  • MILAN and NEW YORK , Dec. 4, 2023 /PRNewswire/ -- Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer's disease (AD), today announced that Chief Executive Officer Paul Kinnon will participate in the TD Cowen Liquid Biopsy Summit , to be held at the Mandarin Oriental Hotel in New York City on December 5, 2023.
  • Mr. Kinnon will serve as a panelist on the Beyond Cancer Panel scheduled from 2:40-3:40 pm ET that day, which will be hosted by Daniel Brennan, Cowen Managing Director, Research, Health Care - Life Science & Diagnostic Tools.
  • Mr. Kinnon noted, "It is gratifying to have the opportunity to participate in this TD Cowen conference highlighting critical advances in blood-based prognostic and diagnostic technologies.
  • We are excited about the potential of AlzoSure® Predict and other new approaches to help revolutionize the treatment of Alzheimer's and other dementias, by giving healthcare providers the tools to easily and cost-effectively determine whether patients are or are not at high risk of declining to AD in the coming years, by enabling drug developers to conduct more rapid and cost-effective clinical trials of new AD therapies and importantly, by ensuring the widest possible access as individuals and their families are able to obtain testing at home if they prefer."

Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure® Predict Alzheimer's Disease Prognostic Technology

Retrieved on: 
Wednesday, October 25, 2023
Knowledge, FDA, Fruit, AD, Ageing, NYSE, Biomarker, CSF, Physician, Apolipoprotein E, Neurology, Data, Conference, AB, Health, Dementia, Protein, PET, Cerebrospinal fluid, DGX, Risk, Marketing, Quest Diagnostics, Test, Diagnosis, Patient, IP, Pharmaceutical industry, Medical imaging, Quest, Alzheimer's disease, Diadem

MILAN and SECAUCUS, N.J., Oct. 25, 2023 /PRNewswire/ -- Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer's disease (AD), today announced that it has formed a strategic collaboration with Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, designed to improve access to high quality blood tests for evaluating the risk of Alzheimer's disease.

Key Points: 
  • Under terms of the agreement, Diadem has licensed exclusive U.S. rights to the intellectual property of its AlzoSure® Predict blood-based prognostic technology to Quest for the purpose of developing, validating and marketing a laboratory-developed test service for providers and patients in the U.S. Financial details of the agreement were not disclosed.
  • "Reliable, convenient and affordable blood tests are essential to the identification of AD risk in early stages, when interventions hold the greatest potential to slow disease progression," said Kathleen Valentine, Vice President and General Manager, Neurology, Quest Diagnostics.
  • Quest Diagnostics has a long-standing history of advancing diagnostic innovation in the field of dementia, including Alzheimer's disease.
  • The company continues to explore the potential of other biomarkers for assessing AD risk that may complement its existing portfolio.

Diadem Presents Data at 2023 AAIC® Showing Its AlzoSure® Blood Test Can Identify Patients at High Risk of Significant Cognitive Decline Due to Alzheimer's Disease

Retrieved on: 
Wednesday, July 19, 2023
Partnership, Alzheimer's disease, Disease, Spondyloarthropathy, Deficit spending, Research, Dementia, Fabricators & Manufacturers Association, International, Biomarker, AAIC, Poster, Data, Risk, Patient, Blood, AUC, CEST, Knowledge, Ageing, AD, FDA, Diadem, Pharmaceutical industry

MILAN and AMSTERDAM, July 19, 2023 /PRNewswire/ -- Diadem SpA, a company developing the first blood-based test for the early prediction of clinical progression to Alzheimer's disease (AD), today announced that study data being presented at the Alzheimer's Association International Conference® 2023 (AAIC®) further strengthens the evidence supporting the prognostic value of Diadem's AlzoSure® Predict blood-based biomarker test, which can accurately identify whether or not individuals over the age of 50 will experience a significant cognitive decline due to AD years before the full onset of symptoms. The study data are included in a scientific poster1 that is being presented today at AAIC® 2023.

Key Points: 
  • The study data are included in a scientific poster1 that is being presented today at AAIC® 2023.
  • It is comprised of individuals who are cognitively normal or who have minimal cognitive impairment, as well as those with dementia due to Alzheimer's disease or a non-AD source.
  • This dataset includes comprehensive medical data on the participants, including blood samples collected over time.
  • Previous research also demonstrated that AlzoSure® Predict can discriminate between the different kinds of dementia with high accuracy.

Diadem Reports New Data Showing Its AlzoSure® Predict Blood Test Can Accurately Identify "Rapid Progressors" Who Will Develop Alzheimer's Disease Within Two Years

Retrieved on: 
Monday, January 9, 2023
Dementia, Amyloid, Clinical trial, Blood, Drug development, Government budget balance, Research, Probability, Alzheimer's disease, Disease, SAN, Patient, AUC, FDA, ADNI, Diadem, AD, Diagnosis, Pharmaceutical industry, Medical imaging

MILAN and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ -- Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced that its researchers have developed computational methods that enable its AlzoSure® Predict prognostic technology to accurately identify individuals who will rapidly progress to AD within two years' time. More than 95% of the patients above the new computational "cutoff" used to define "rapid progressors" were shown to progress to AD within two years' time, regardless of their baseline diagnosis. Using a modified form of the new approach, Diadem was able to do even better, accurately identifying a cohort where 100% of the patients progressed to AD within two years, while none of the patients not included in the modified cutoff cohort did so.

Key Points: 
  • The computational analysis were developed using a relatively limited number of patient samples from major international longitudinal patient databases.
  • The results will be further validated and expanded, and these analyses are already underway using global cohorts of qualified biological samples.
  • AlzoSure® Predict can allow drug developers to screen, enrich and stratify patient populations to facilitate Alzheimer's disease clinical trials.
  • Previous research also demonstrated that AlzoSure® Predict can discriminate between the different kinds of dementia with high accuracy.

The Dragon Isles Have Awakened—World of Warcraft®: Dragonflight is Now Live!

Retrieved on: 
Monday, November 28, 2022
Software, Online, Consumer Electronics, General Entertainment, Mobile Entertainment, Technology, Electronic Games, Entertainment, Emerald, IOS, Heart, Classic, PlayStation, Blizzard Entertainment, Blizzard, History, Activision Blizzard, Horde, World of Warcraft, Multimedia, Xbox, Tabard, Friends, MDY Industries, LLC v. Blizzard Entertainment, Inc., SRP, Nintendo Switch, ATVI, Annual report, World of Warcraft Classic, Game of the Year, Risk, Android, HUD, Diadem, Form 10-K, Activision, Acquisition, Design, Video game, Cassette tape, Video game console, Azeroth

World of Warcraft: Dragonflight, the ninth expansion to Blizzard Entertainments critically acclaimed massively multiplayer online role-playing game, is now live!

Key Points: 
  • World of Warcraft: Dragonflight, the ninth expansion to Blizzard Entertainments critically acclaimed massively multiplayer online role-playing game, is now live!
  • Heroes of the Horde and Alliance are called back to Azeroth to explore the mystical Dragon Isles and its ancient secrets, where the dragon aspects have returned to reclaim their kingdom and ancestral home.
  • Dragonflight introduces the first ever race/class combo for World of Warcraft, the dracthyr Evoker.
  • Players can channel the magics of the dragon flights, maneuvering across battlefields as they heal their allies or damage their foes while utilizing all-new Empowered spellcasting.

Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSure® Predict Prognostic Test for Alzheimer's Disease

Retrieved on: 
Monday, November 21, 2022
Doctor of Philosophy, Head, AD, Dementia, MD, University of Siena, Biomarker, Foreign policy, Precision medicine, University, Clinical trial, Blood, University of Cambridge, Research, Dhaneswar Rath Institute of Engineering and Management Studies, Novartis, Government budget balance, CFO, Biology, Patient, Sanofi, GlaxoSmithKline, Diagnosis, CMO, University of Glasgow, Molecular medicine, Chartered accountant, Disease, Genomics, Laboratory, Management, Pharmaceutical industry, Medical device, Medical imaging, Teva, Alzheimer's disease, EU, Engineering, Takeda, Operation, Diadem

MILAN, Nov. 21, 2022 /PRNewswire/ -- Diadem SpA, (or Diadem US, Inc.) a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced key additions to its senior management team. Sam Agus, MD, has been appointed Chief Medical Officer (CMO), James Clarke, PhD, has been named Head, External Affairs and Collaborations, and Peter Bream is Diadem's new Chief Financial Officer (CFO). They join Simona Piccirella, PhD, Vice President of Operations and Development and Chief Executive Officer Paul Kinnon at Diadem.

Key Points: 
  • They join Simona Piccirella, PhD, Vice President of Operations and Developmentand Chief Executive Officer Paul Kinnon at Diadem.
  • Simona has already played a major role in growing Diadem and developing the AlzoSure technology to this stage.
  • Their contributions will be instrumental as we prepare for the commercialization of AlzoSure Predict in the new year."
  • The company is also developing AlzoSure Confirm, a blood-based diagnostic test for AD that has shown promising results in early studies.

Master the Skies of the Dragon Isles when World of Warcraft® Dragonflight Soars on November 28

Retrieved on: 
Thursday, September 29, 2022
Software, Online, Consumer Electronics, General Entertainment, Mobile Entertainment, Technology, Electronic Games, Entertainment, HUD, Software, ATVI, Activision Blizzard, Form 10-K, Activision, Blizzard Entertainment, Forward-looking statement, Risk, Art, Diadem, UI, Friends, SRP, World of Warcraft, Rise of Incarnates, NASDAQ, MDY Industries, LLC v. Blizzard Entertainment, Inc., Multimedia, Annual report, Game of the Year, Asmongold, Drake's, Atmosphere, Blizzard, Color, Video game, Video game console, Entertainment, Online shopping, Cassette tape, Dragonriders of Pern (video game)

Players will discover the Dragon Isles and explore four new zoneseach themed around and revealing more about the ancient dragon aspectsall lovingly crafted by the World of Warcraft development team for veteran and new players alike.

Key Points: 
  • Players will discover the Dragon Isles and explore four new zoneseach themed around and revealing more about the ancient dragon aspectsall lovingly crafted by the World of Warcraft development team for veteran and new players alike.
  • As the Dragon Isles awaken, so too do long-forgotten secrets, and players will traverse land and sky as they explore what the Dragon Isles has to offer.
  • Soar through the skies as you master the all-new skill-based art of Dragonriding, which allows players to take to the air on the back of their own Dragon Isles Drake.
  • Dragonflight is available for digital pre-purchase as a Base edition ($49.99 SRP), Heroic edition ($69.99 SRP), and Epic edition ($89.99).

Viviota Announces New DIAdem Analytics Webinar Series for Engineers

Retrieved on: 
Monday, September 26, 2022
Engineering, Digital transformation, Time, Software, NI, Organization, Data management, Diadem, Data analysis, Ministry of Education (Malaysia), CRO, Solution, Medical device, Typesetting, Mobile phone, Boilermaker

All attendees of this free webinar series will receive Viviota DIAdem Tools+ Software, which works to enhance your existing installation of DIAdem with a wide range of powerful and time saving features for all DIAdem users from beginners to experts.

Key Points: 
  • All attendees of this free webinar series will receive Viviota DIAdem Tools+ Software, which works to enhance your existing installation of DIAdem with a wide range of powerful and time saving features for all DIAdem users from beginners to experts.
  • 5 Powerful Tricks to up your DIAdem Game, Presented by Julia Dawkins
    Whether you are new to DIAdem or looking to enhance your skills, this webinar will cover some of the most overlooked capabilities using DIAdem.
  • DIAdem Advanced: Python Scripting & Building a Data Plugin, Presented by Julia Dawkins
    Getting started with DIAdem may be simple, however getting the most out of DIAdem is more complex.
  • He has been using DIAdem for four years and has most recently been leading workshops to help automotive engineers use DIAdem to simplify their analysis workflows.

Diadem Presents Data at 2022 Alzheimer's Association International Conference® Showing Its Blood-Based Biomarker Test Can Both Diagnose and Predict Alzheimer's Disease

Retrieved on: 
Tuesday, August 2, 2022
AAIC, AUC, Fabricators & Manufacturers Association, International, SAN, Ageing, Biomarker, Diadem, Conference, AD, Patient, MILAN, Medical device, Medical imaging, Alzheimer's disease

SAN DIEGO and MILAN, Aug. 2, 2022 /PRNewswire/ -- Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer's disease (AD), today reported that study data presented at the Alzheimer's Association International Conference® 2022 (AAIC®) in San Diego, USA confirms the strong diagnostic value of Diadem's AlzoSure® Predict blood based biomarker test, as well as its excellent performance in identifying whether or not individuals will progress to AD years before the manifestation of clinical symptoms. The study data are included in a poster presentation1 that is being presented at AAIC® 2022 on August 3, 2022.

Key Points: 
  • The study data are included in a poster presentation1 that is being presented at AAIC 2022 on August 3, 2022.
  • The data Diadem is presenting at AAIC 2022 confirms the diagnostic performance of AlzoSure Predict for Alzheimer's disease and highlights its potential as a prognostic test.
  • The company is developing the first blood-based prognostic test for the early detection of dementia, with a focus on Alzheimer's disease.
  • The company is also developing AlzoSure Confirm, a blood-based diagnostic test for AD that has shown promising results in early studies.

Take Flight in the Dragon Isles when World of Warcraft® Dragonflight Lands Later This Year—Pre-purchase Available Now

Retrieved on: 
Tuesday, June 21, 2022
Electronic Games, Technology, Entertainment, Online, Mobile Entertainment, Other Entertainment, General Entertainment, Licensing (Entertainment), Consumer Electronics, ATVI, Freedom, UI, Blizzard Entertainment, Risk, World of Warcraft, Forward-looking statement, Annual report, Game of the Year, NASDAQ, Activision, Color, History, Software, SRP, HUD, Blizzard, Activision Blizzard, MDY Industries, LLC v. Blizzard Entertainment, Inc., Multimedia, Art, Diadem, Form 10-K, Battle.net, Video game, Video game console, Cassette tape, Azeroth, Warcraft

In Dragonflight, players will embark to the awakening Dragon Isles, the origin place of dragonkind, where the fabled dragon aspects have returned to claim their rightful home.

Key Points: 
  • In Dragonflight, players will embark to the awakening Dragon Isles, the origin place of dragonkind, where the fabled dragon aspects have returned to claim their rightful home.
  • Dragonriding, a new method of aerial movement, empowers players to soar through the skies of each new area in style atop customizable Dragon Isles Drakes.
  • Dragonflight is a return to Azeroth, and the freedom and exploration that World of Warcraft is known for," said Executive Producer Holly Longdale.
  • Dragonflight is available for digital pre-purchase as a Base edition ($49.99 SRP), Heroic edition ($69.99 SRP), and Epic edition ($89.99).